Presentation is loading. Please wait.

Presentation is loading. Please wait.

Short course of systemic corticosteroids in sinonasal polyposis: A double-blind, randomized, placebo-controlled trial with evaluation of outcome measures 

Published byAnke Schuler Modified over 5 years ago

Similar presentations

Presentation on theme: "Short course of systemic corticosteroids in sinonasal polyposis: A double-blind, randomized, placebo-controlled trial with evaluation of outcome measures "— Presentation transcript:

1 Short course of systemic corticosteroids in sinonasal polyposis: A double-blind, randomized, placebo-controlled trial with evaluation of outcome measures  Pravin Hissaria, DM, William Smith, PhD, Peter J. Wormald, MD, James Taylor, FRANZCR, Mathew Vadas, PhD, David Gillis, FRCPA, Frank Kette, PhD  Journal of Allergy and Clinical Immunology  Volume 118, Issue 1, Pages (July 2006) DOI: /j.jaci Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

2 Fig 1 Scores at baseline and after treatment of subjects with sinonasal polyposis with 50 mg of prednisolone or placebo daily for 14 days. A, Mean ± SEM of average (modified) RSOM-31 score for all 31 parameters (n = 20 in each group). B, Mean ± SEM of average RSOM score for nasal subscales only (6 parameters, n = 20 in each group). C, Mean ± SEM MRI score (n = 17 in prednisolone-treated and n = 19 in placebo-treated patients). D, Mean ± SEM percentage change in polyp size on nasendoscopy (largest polyps normalized to 100%, n = 15 in prednisolone-treated and n = 17 in placebo-treated patients). ∗P < .05; ∗∗P < .005 (Student t test). Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Download ppt "Short course of systemic corticosteroids in sinonasal polyposis: A double-blind, randomized, placebo-controlled trial with evaluation of outcome measures "

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.
Characteristics of childhood peanut allergy in the Australian Capital Territory, 1995 to 2007 Raymond James Mullins, MBBS, PhD, FRACP, FRCPA, Keith B.G.

Characteristics of childhood peanut allergy in the Australian Capital Territory, 1995 to 2007 Raymond James Mullins, MBBS, PhD, FRACP, FRCPA, Keith B.G.
Severe adult-onset asthma: A distinct phenotype

Severe adult-onset asthma: A distinct phenotype
The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.

The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.
Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS 

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS 
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: A double-blind, placebo-controlled randomized.

Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: A double-blind, placebo-controlled randomized.
Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery  Albertien A.C. Aukema,

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery  Albertien A.C. Aukema,
Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Robert M. Naclerio, MD, Jayant Pinto, MD, Fuad Baroody, MD 

Robert M. Naclerio, MD, Jayant Pinto, MD, Fuad Baroody, MD 
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.

Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.
Oral steroids and doxycycline: Two different approaches to treat nasal polyps  Thibaut Van Zele, MD, PhD, Philippe Gevaert, MD, PhD, Gabriele Holtappels,

Oral steroids and doxycycline: Two different approaches to treat nasal polyps  Thibaut Van Zele, MD, PhD, Philippe Gevaert, MD, PhD, Gabriele Holtappels,
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,
Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael.

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael.

Similar presentations

Ads by Google